132 related articles for article (PubMed ID: 16942440)
1. Complete regression of large solid tumors using engineered drug-resistant hematopoietic cells and anti-CD137 immunotherapy.
McMillin DW; Hewes B; Gangadharan B; Archer DR; Mittler RS; Spencer HT
Hum Gene Ther; 2006 Aug; 17(8):798-806. PubMed ID: 16942440
[TBL] [Abstract][Full Text] [Related]
2. A gene transfer strategy for making bone marrow cells resistant to trimetrexate.
Spencer HT; Sleep SE; Rehg JE; Blakley RL; Sorrentino BP
Blood; 1996 Mar; 87(6):2579-87. PubMed ID: 8630426
[TBL] [Abstract][Full Text] [Related]
3. Trimetrexate inhibits progression of the murine 32Dp210 model of chronic myeloid leukemia in animals expressing drug-resistant dihydrofolate reductase.
Sweeney CL; Frandsen JL; Verfaillie CM; McIvor RS
Cancer Res; 2003 Mar; 63(6):1304-10. PubMed ID: 12649191
[TBL] [Abstract][Full Text] [Related]
4. Retroviral vectors containing a variant dihydrofolate reductase gene for drug protection and in vivo selection of hematopoietic cells.
Allay JA; Galipeau J; Blakley RL; Sorrentino BP
Stem Cells; 1998; 16 Suppl 1():223-33. PubMed ID: 11012166
[TBL] [Abstract][Full Text] [Related]
5. Increased resistance to nitrogen mustards and antifolates following in vitro selection of murine fibroblasts and primary hematopoietic cells transduced with a bicistronic retroviral vector expressing the rat glutathione S-transferase A3 and a mutant dihydrofolate reductase.
Belzile JP; Karatzas A; Shiu HY; Létourneau S; Palerme JS; Cournoyer D
Cancer Gene Ther; 2003 Aug; 10(8):637-46. PubMed ID: 12872145
[TBL] [Abstract][Full Text] [Related]
6. In vivo selection of antifolate-resistant transgenic hematopoietic stem cells in a murine bone marrow transplant model.
Warlick CA; Diers MD; Wagner JE; McIvor RS
J Pharmacol Exp Ther; 2002 Jan; 300(1):50-6. PubMed ID: 11752096
[TBL] [Abstract][Full Text] [Related]
7. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
8. Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer.
Gauttier V; Judor JP; Le Guen V; Cany J; Ferry N; Conchon S
Int J Cancer; 2014 Dec; 135(12):2857-67. PubMed ID: 24789574
[TBL] [Abstract][Full Text] [Related]
9. Post-transplant methotrexate administration leads to improved curability of mice bearing a mammary tumor transplanted with marrow transduced with a mutant human dihydrofolate reductase cDNA.
Zhao SC; Banerjee D; Mineishi S; Bertino JR
Hum Gene Ther; 1997 May; 8(8):903-9. PubMed ID: 9195212
[TBL] [Abstract][Full Text] [Related]
10. Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene.
Takebe N; Zhao SC; Adhikari D; Mineishi S; Sadelain M; Hilton J; Colvin M; Banerjee D; Bertino JR
Mol Ther; 2001 Jan; 3(1):88-96. PubMed ID: 11162315
[TBL] [Abstract][Full Text] [Related]
11. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
[TBL] [Abstract][Full Text] [Related]
12. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic vaccination with tumor cells that engage CD137.
Hellstrom KE; Hellstrom I
J Mol Med (Berl); 2003 Feb; 81(2):71-86. PubMed ID: 12601523
[TBL] [Abstract][Full Text] [Related]
14. Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: a method to modulate gene expression.
Mayer-Kuckuk P; Banerjee D; Malhotra S; Doubrovin M; Iwamoto M; Akhurst T; Balatoni J; Bornmann W; Finn R; Larson S; Fong Y; Gelovani Tjuvajev J; Blasberg R; Bertino JR
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3400-5. PubMed ID: 11891321
[TBL] [Abstract][Full Text] [Related]
15. Retroviral coexpression of thymidylate synthase and dihydrofolate reductase confers fluoropyrimidine and antifolate resistance.
Fantz CR; Shaw D; Moore JG; Spencer HT
Biochem Biophys Res Commun; 1998 Feb; 243(1):6-12. PubMed ID: 9473470
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy with agonistic anti-CD137: two sides of a coin.
Sun Y; Chen JH; Fu Y
Cell Mol Immunol; 2004 Feb; 1(1):31-6. PubMed ID: 16212918
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy.
Dubrot J; Palazón A; Alfaro C; Azpilikueta A; Ochoa MC; Rouzaut A; Martinez-Forero I; Teijeira A; Berraondo P; Le Bon A; Hervás-Stubbs S; Melero I
Int J Cancer; 2011 Jan; 128(1):105-18. PubMed ID: 20309938
[TBL] [Abstract][Full Text] [Related]
18. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.
Wilcox RA; Flies DB; Zhu G; Johnson AJ; Tamada K; Chapoval AI; Strome SE; Pease LR; Chen L
J Clin Invest; 2002 Mar; 109(5):651-9. PubMed ID: 11877473
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate accumulates to similar levels in animals transplanted with normal versus drug-resistant transgenic marrow.
Belur LR; Boelk-Galvan D; Diers MD; McIvor RS; Zimmerman CL
Cancer Res; 2001 Feb; 61(4):1522-6. PubMed ID: 11245460
[TBL] [Abstract][Full Text] [Related]
20. Drug-resistant dihydrofolate reductases: generation, expression and therapeutic application.
McIvor RS
Bone Marrow Transplant; 1996 Dec; 18 Suppl 3():S50-4. PubMed ID: 8971409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
